» Articles » PMID: 35545901

Closing the Hepatitis C Treatment Gap: United States Strategies to Improve Retention in Care

Overview
Journal J Viral Hepat
Specialty Gastroenterology
Date 2022 May 12
PMID 35545901
Authors
Affiliations
Soon will be listed here.
Abstract

The hepatitis C virus (HCV) treatment landscape is shifting given the advent of direct-acting antivirals and a global call to action by the World Health Organization. Eliminating HCV is now an issue of healthcare delivery. Treatment is limited by the complexity of the HCV care continuum, expensive therapy and competing health burdens experienced by an underserved HCV population. The objective of this literature review was to assess strategies to improve retention in HCV care, with particular focus on those implemented in the United States. We identified barriers in HCV care retention and propose solutions to increase HCV treatment delivery. The following recommendations are herein described: improving the cohesion of health services through localized care and integrated case management, expanding the supply of non-specialist HCV treatment providers, leveraging patient navigators and care coordinators, improving adherence through directly observed therapy and reducing cost barriers through value-based payment and pharmaceutical subscription models.

Citing Articles

Knowledge of, and attitude towards, the treatment of hepatitis C in people who inject drugs.

Roser P, Brunstein M, Specka M, Timm J, Kuhnhold S, Schifano F Harm Reduct J. 2024; 21(1):160.

PMID: 39198822 PMC: 11351267. DOI: 10.1186/s12954-024-01068-w.


Current perspectives of viral hepatitis.

Usuda D, Kaneoka Y, Ono R, Kato M, Sugawara Y, Shimizu R World J Gastroenterol. 2024; 30(18):2402-2417.

PMID: 38764770 PMC: 11099385. DOI: 10.3748/wjg.v30.i18.2402.

References
1.
Trusheim M, Cassidy W, Bach P . Alternative State-Level Financing for Hepatitis C Treatment-The "Netflix Model". JAMA. 2018; 320(19):1977-1978. DOI: 10.1001/jama.2018.15782. View

2.
Roebuck M, Liberman J . Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid. Am J Manag Care. 2019; 25(8 Suppl):S131-S139. View

3.
Anderson E, Galbraith J, Deering L, Pfeil S, Todorovic T, Rodgers J . Continuum of Care for Hepatitis C Virus Among Patients Diagnosed in the Emergency Department Setting. Clin Infect Dis. 2017; 64(11):1540-1546. DOI: 10.1093/cid/cix163. View

4.
Lin M, Kramer J, White D, Cao Y, Tavakoli-Tabasi S, Madu S . Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017; 46(10):992-1000. PMC: 5800315. DOI: 10.1111/apt.14328. View

5.
Woodrell C, Weiss J, Branch A, Gardenier D, Krauskopf K, Kil N . Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents. J Addict Med. 2015; 9(5):405-10. PMC: 4672248. DOI: 10.1097/ADM.0000000000000147. View